Sertraline for the treatment of depression in Parkinson's disease.
Although antidepressant medications are commonly used to treat depression in Parkinson's disease (PD), little information is available regarding their safety and efficacy in this condition. Sertraline is a relatively selective serotonin reuptake inhibitor with some dopamine reuptake inhibitor activity. It has a favorable tolerability profile, especially in the elderly. We undertook an open-label pilot evaluation of the safety and efficacy of sertraline to treat depression in PD. A total of 15 patients with PD and depression participated in the study. Sertraline was introduced at a daily dose of 25 mg for 1 week and then increased to 50 mg/day. Patients underwent evaluation at baseline and at a final visit approximately 7 weeks later. Sertraline was generally well tolerated, but five patients experienced side effects, and two discontinued medication. Patients taking selegiline experienced more adverse effects. Beck Depression Inventory scores improved significantly (mean +/- SE = 16.0 +/- 2.0 vs 11.7 +/- 1.9, p = 0.03), and Unified Parkinson's Disease Rating Scale and energy-level scores were unchanged. These results suggest that sertraline may be a useful treatment for depression in PD. As substantial placebo effects can occur in studies of PD and depression, placebo-controlled, double-blind studies are warranted.
Hauser
R A
RA
Department of Neurology, University of South Florida, Tampa, USA.
Zesiewicz
T A
TA
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003863:Depression / Q000150:complications / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D010865:Pilot Projects; D011446:Prospective Studies; D012642:Selegiline / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline; D012720:Severity of Illness Index; D016896:Treatment Outcome
D015057:1-Naphthylamine; D018687:Antidepressive Agents, Second-Generation; D000978:Antiparkinson Agents; D012642:Selegiline; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline